Bortezomib is effective in the treatment of multiple myeloma. The mechanisms involve inhibiting NF-kB pathways, accumulating misfolded proteins, and eventually leading to apoptosis in those rapid growth cells. I have a concern here. Whether the level of cancer-promoting proteins will increase after proteasome inhibitor treatment since the protein degradation pathway has been blocked? And whether those oncoproteins could inhibit proteasome inhibitor-induced cell death?
Guangqi Wang
Even though PIs have effective anti-tumor toxicity，it’s not the only way to degrade protein by proteasomes. And the gene expression also impacts protein level, which is altered under chemotherapies.
0 votes
0 thanks
More Yan Cheng's questions See All
Similar questions and discussions